ovariancancer
Latest
FDA greenlights 23andMe's direct-to-consumer cancer risk test
Cancer screening isn't all that accessible -- you typically need an obvious genetic background that suggests you're at risk, which doesn't help if you slip between those cracks. You shouldn't have to run that gauntlet for much longer. The US Food and Drug Administration has approved a 23andMe direct-to-consumer test that details the risks of breast, ovarian and prostate cancer based on BRCA1 and BRCA2 genetic mutations. Once the report is available, you wouldn't have to worry about qualifying for a screening -- you could send in a saliva sample and find out on your own terms.
